Premium
Pathophysiology of BRONJ: Drug‐related osteoclastic disease of the jaw
Author(s) -
Ikebe Tetsuro
Publication year - 2013
Publication title -
oral science international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.256
H-Index - 13
eISSN - 1881-4204
pISSN - 1348-8643
DOI - 10.1016/s1348-8643(12)00045-6
Subject(s) - osteonecrosis of the jaw , medicine , bisphosphonate , disease , osteoclast , bisphosphonate associated osteonecrosis of the jaw , drug , intensive care medicine , oncology , bioinformatics , osteoporosis , pharmacology , receptor , biology
Since the first article about bisphosphonate‐related osteonecrosis of the jaw (BRONJ) was published in 2003, clinical and basic research for BRONJ has continued worldwide to understand this novel disease. Several organizations have proposed the definition, diagnostic criteria, risk factors, and treatment strategy for BRONJ. Recently, some new drugs used for cancer patients such as bevacizumab and sunitinib have also been reported to be involved in osteonecrosis of the jaw (ONJ). Because ONJ appears to be initially derived from osteoclast inhibition, a new category of diseases named as “drug‐related osteoclastic disease of the jaw” may be assumed. Considering the accumulated knowledge related to BRONJ, including osteoclast biology, bisphosphonate pharmacology, animal experiments, and clinicopathological findings, a perspective of BRONJ from the pathophysiological viewpoint is proposed in this review.